JGJarosław Gorący

Jarosław Gorący

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jarosław Gorący has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022

    by Jacek Kubica, Piotr Adamski, Jerzy R. Ładny, Jarosław Kaźmierczak, Tomasz Fabiszak, Krzysztof J. Filipiak, Robert Gajda, Mariusz Gąsior, Zbigniew Gąsior, Robert Gil, et al.


  • Open Access

    Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

    by Łukasz Kołtowski, Jacek Legutko, Krzysztof J. Filipiak, Artur Dziewierz, Stanisław Bartuś, Paweł Buszman, Piotr Buszman, Dariusz Ciećwierz, Maciej Dąbrowski, Sławomir Dobrzycki, et al.


  • Open Access

    E-selectin gene haplotypes are associated with the risk of myocardial infarction

    by Jarosław Gorący, Mariusz Kaczmarczyk, Andrzej Ciechanowicz, Krzysztof Safranow, Joanna Gorący, Katarzyna Jakubowska, Dariusz Chlubek, Iwona Gorący

    Introduction Endothelial dysfunction is one of the most important factors implicated in the pathogenesis of coronary artery disease (CAD). The aim of this study was to investigate the association of the E-selectin gene (SELE) with CAD and CAD-related traits using tagging polymorphisms....


  • Open Access

    Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint

    by Jacek Kubica, Piotr Adamski, Przemysław Paciorek, Jerzy R. Ładny, Zbigniew Kalarus, Waldemar Banasiak, Wacław Kochman, Jarosław Gorący, Beata Wożakowska-Kapłon, Eliano Pio Navarese, et al.

    A group of Polish experts in cardiology and emergency medicine, encouraged by the European Society of Cardiology (ESC) guidelines, have recently published common recommendations for medical emergency teams regarding the pre-hospital management of patients with acute coronary syndrome. Due to the recent publication of the 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation and 2017 focused update on dual antiplatelet therapy in coronary artery disease the current panel of experts decided to update the previous standpoint. Moreover, new data coming from studies presented after the previous document was issued were also taken into consideration. A group of Polish experts in cardiology and emergency medicine, encouraged by the European Society of Cardiology (ESC) guidelines, have recently published common recommendations for medical emergency teams regarding the pre-hospital management of patients with acute coronary syndrome. Due to the recent publication of the 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation and 2017 focused update on dual antiplatelet therapy in coronary artery disease the current panel of experts decided to update the previous standpoint. Moreover, new data coming from studies presented after the previous document was issued were also taken into consideration.


  • Vasculitis or coronary atherosclerosis? Optical coherence tomography images in polyarteritis nodosa

    by Maciej Lewandowski, Jarosław Gorący, Irmina Kossuth, Małgorzata Peregud-Pogorzelska


  • Angiographic severity of coronary artery disease and cardiovascular risk in acute coronary syndrome in patients with metabolic syndrome

    by Katarzyna Widecka, Krzysztof Safranow, Maciej Lewandowski, Krzysztof Przybycień, Jarosław Gorący, Zdzisława Kornacewicz-Jach

    Background: Extent of angiographic lesions, size of infarct and in-hospital and distant prognosis in patients with the metabolic syndrome have been not clearly determined. Detailed knowledge of markers both for ACS occurrence as well as those affecting early and further prognosis will have key significance at taking correct preventive and therapeutic decisions. Aim: Comparing in patients with first ACS treated with coronary angioplasty the advancement of coronary disease and the cardiovascular risk evaluated using GRACE 2.0 risk score and the size of the left ventricular ejection fraction depending on co-occurrence of metabolic syndrome Methods: The research was conducted in the group of 160 subsequent patients of the Cardiology Clinic of PUM, hospitalized due to their first in life ACS, treated using the coronary angioplasty, being at the age of 18-70 years. . For all patients the coronarography, that is performed as a routine before angioplasty, was assessed. Before checking out of the hospital the echocardiographic test of the left ventricle function was performed. In all patients the metabolic syndrome was evaluated according to NCEP ATP III criteria. In blood samples taken from the patients the following was marked using routine methods: heart necrosis markers, creatinine concentration ionogram, lipid profile, glucose and insulin concentration, and homeostatic model was calculated. On the basis of acquired data, for all patients the cardiovascular risk was evaluated according to GRACE 2.0 score, using a computer calculator available in the GRACE 2.0 Internet site (www.gracescore.org). Statistical analysis of obtained results was performed using the STATISTICA software varsion 12.0 from StatSoft Inc. Results: Metabolic syndrome criteria were met by 53.5% of examined patients. The examined patients, regardless occurrence of metabolic syndrome, were not different in angiographic advancements of coronary disease and cardiovascular risk as evaluated with the GRACE 2.0 score. In patients with the metabolic syndrome a significantly higher left ventricular ejection fraction was found, compared to patients without this syndrome. In the whole examined group evaluated as a whole, the coronary disease angiographic advancement expressed as the epicardial artery affected correlated alternately positively correlated alternatively positively with age, BMI, insulin and HOMA-IR concentration. The cardiovascular risk assessed with the GRACE 2.0 score correlated with age, BMI, insulin concentration on fasting and with HOMA-IR, and negatively with systolic pressure, diastolic pressure and triglycerides concentration. The multiple regression model for predicting the left ventricular ejection fraction value indicated the strongest prognostic factor for LFEF was the type of acute coronary syndrome. Among other examined parameters, independent and statistically significant effect on the left ventricular ejection fraction had pulse value, Killip class, HDL cholesterol concentration, genetic predisposition toward cardiovascular diseases and the presence of metabolic syndrome. Conclusions: Observed correlative dependence between the coronary disease angiographic advancement and the age, BMI, insulin resistance confirm importance of these parameters in development of the coronary atherosclerosis. Demonstrated correlations between estimated cardiovascular risk, measured using GRACE score and insulin resistance confirm prognostic importance of metabolic parameters in patients after their first ACS. In patients with the first ACS for predicting the discharge fraction of the left ventricle, the most useful is the type of acute coronary syndrome, and among other evaluated parameters the presence of the metabolic syndrome and the pulse value, Killip class, HDL cholesterol concentration and genetic predisposition toward cardiovascular diseases. Background: Extent of angiographic lesions, size of infarct and in-hospital and distant prognosis in patients with the metabolic syndrome have been not clearly determined. Detailed knowledge of markers both for ACS occurrence as well as those affecting early and further prognosis will have key significance at taking correct preventive and therapeutic decisions. Aim: Comparing in patients with first ACS treated with coronary angioplasty the advancement of coronary disease and the cardiovascular risk evaluated using GRACE 2.0 risk score and the size of the left ventricular ejection fraction depending on co-occurrence of metabolic syndrome Methods: The research was conducted in the group of 160 subsequent patients of the Cardiology Clinic of PUM, hospitalized due to their first in life ACS, treated using the coronary angioplasty, being at the age of 18-70 years. . For all patients the coronarography, that is performed as a routine before angioplasty, was assessed. Before checking out of the hospital the echocardiographic test of the left ventricle function was performed. In all patients the metabolic syndrome was evaluated according to NCEP ATP III criteria. In blood samples taken from the patients the following was marked using routine methods: heart necrosis markers, creatinine concentration ionogram, lipid profile, glucose and insulin concentration, and homeostatic model was calculated. On the basis of acquired data, for all patients the cardiovascular risk was evaluated according to GRACE 2.0 score, using a computer calculator available in the GRACE 2.0 Internet site (www.gracescore.org). Statistical analysis of obtained results was performed using the STATISTICA software varsion 12.0 from StatSoft Inc. Results: Metabolic syndrome criteria were met by 53.5% of examined patients. The examined patients, regardless occurrence of metabolic syndrome, were not different in angiographic advancements of coronary disease and cardiovascular risk as evaluated with the GRACE 2.0 score. In patients with the metabolic syndrome a significantly higher left ventricular ejection fraction...


  • Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts’ standpoint

    by Jacek Kubica, Piotr Adamski, Przemysław Paciorek, Jerzy R. Ładny, Zbigniew Kalarus, Waldemar Banasiak, Wacław Kochman, Jarosław Gorący, Beata Wożakowska-Kapłon, Eliano Pio Navarese, et al.


  • Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention

    by Szymon Olędzki, Zdzisława Kornacewicz-Jach, Krzysztof Safranow, Radosław Kiedrowicz, Barbara Gawrońska-Szklarz, Maria Jastrzębska, Jarosław Gorący

    Antiplatelet response to clopidogrel and its influence upon the risk of cardiovascular adverse events among patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) has not been investigated fully.


  • Scuba diving, patent foramen ovale and heart rhythm disturbances: The role of underwater Holter monitoring—Case report

    by Szymon Olędzki, Andrzej Wojtarowicz, Edyta Płońska‐Gościniak, Maciej Lewandowski, Jarosław Gorący

    Patent foramen ovale (PFO) is thought to be a risk factor for decompression illness (DCI). Catheter‐based closure procedure reduces the risk of DCI in selected scuba divers with PFO. Major complication of invasive approach are rare, minor, especially heart rhythm disturbances are reported relatively often. We describe a case of 41‐year‐old diver, who underwent PFO closure due to recurrent DCI events. Afterward, he experienced no DCI symptoms; however, he complained about feeling of the heart beating during a submersion. Arrhythmia should be considered as a life‐threatening for scuba diver, thus we performed underwater ECG monitoring and exclude the arrhythmia.


  • Open Access

    Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts’ standpoint

    by Jacek Kubica, Piotr Adamski, Przemysław Paciorek, Jerzy R. Ładny, Zbigniew Kalarus, Waldemar Banasiak, Wacław Kochman, Jarosław Gorący, Beata Wożakowska-Kapłon, Eliano Pio Navarese, et al.